Neural Differentiation Culture Medium

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current neural induction protocols for human pluripotent stem cells are inefficient, resulting in heterogeneous and poorly reproducible neural populations, often requiring animal-derived products and sorting steps, which are time-consuming and not compatible with Good Manufacturing Practice (GMP) standards.

Innovation Solution

A culture medium inhibiting the BMP and TGF/activin/nodal signaling pathways, specifically containing noggin and SB431542, is used to culture pluripotent cells, eliminating the need for animal-derived products and sorting steps, thereby producing a homogeneous population of neural precursors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If current neural induction protocols are used, then neural cell production is achieved, but the resulting population is heterogeneous and poorly reproducible

Engineering Contradiction:
Improvehomogeneity of neural populationVSAvoidreproducibility of neural induction
Core Design Contradiction:
Manufacturing precisionVSReliability

Solution Approach 1:

The patent applies parameter changes by precisely controlling signaling pathway inhibitors (BMP and TGF/activin/nodal) in the culture medium to achieve synchronous neural differentiation. This controlled parameter adjustment ensures homogeneous neural precursor populations with high reproducibility across experiments, resolving the contradiction between population homogeneity and reproducibility.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses small molecule inhibitors (SB431542 for TGF/activin/nodal pathway and BMP inhibitors) as intermediaries to mediate the differentiation process. These intermediaries provide precise control over signaling pathways, enabling reproducible generation of homogeneous neural populations without requiring animal-derived products or sorting steps.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Manufacturing precision

If sorting or selection steps are implemented to obtain pure neural populations, then cell purity is improved, but time consumption increases and cell viability decreases

Engineering Contradiction:
Improvepurity of neural precursorsVSAvoidtime for sorting step
Core Design Contradiction:
Manufacturing precisionVSLoss of time

Solution Approach 1:

The patent applies preliminary action by optimizing the differentiation protocol to directly produce pure neural precursor populations without requiring subsequent sorting steps. The controlled inhibition of BMP and TGF/activin/nodal signaling pathways from the outset ensures synchronous differentiation and high purity, eliminating time-consuming selection processes and preserving cell viability.

Inventive Principle:
Principle #10Preliminary action

3Productivity

If animal-derived products are used in culture medium, then cell growth is supported, but GMP compatibility is compromised

Engineering Contradiction:
Improvecell growth efficiencyVSAvoidGMP compatibility
Core Design Contradiction:
ProductivityVSEase of manufacture

Solution Approach 1:

The patent applies the extraction principle by removing animal-derived products (such as serum and feeder layers) from the culture system. The differentiated protocol uses defined chemical inhibitors and synthetic medium components that support neural precursor growth and differentiation while maintaining GMP compatibility, thus extracting the harmful element while preserving productivity.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses small molecule inhibitors that replicate the function of complex animal-derived factors. Instead of using undefined serum components, the protocol employs well-characterized chemical compounds (SB431542 and BMP inhibitors) that copy the necessary biological activities in a defined, GMP-compatible manner, maintaining cell growth efficiency while enabling manufacturing compliance.

Inventive Principle:
Principle #26Copying

Data Source

PatentEP2356218B1Method and medium for neural differentiation of pluripotent cells
Publication Date: 2017.05.03 INSERM INST NAT DE LA SANTE & DE LA RE
  • EP2356218B1 patent drawingFigure 1A~1C
  • EP2356218B1 patent drawingFigure 2A~2B
  • EP2356218B1 patent drawingFigure 3A~3B

AI summary

The invention relates to a culture medium comprising an inhibitor of the BMP signaling pathway; and an inhibitor of the TGF/activin/nodal signaling pathway and to a method for obtaining a population of neural precursors using said culture medium.